Bolstering Stem Cells Against Off-Target Effects of Cancer Therapies

Video

The chief executive and chief medical officers of Vor Biopharma discussed their focus on AML, CD33, and their lead program VOR33.

“If the patient relapses, the 2-year survival is less than 20%. We want to radically change that, and make transplant what it should be, which is really a curative therapy for patients such that they can live normal, healthy, productive lives following a bone marrow transplant. We hope that our approach will be able to achieve that.”

Vor Biopharma hopes to develop treatments for acute myeloid leukemia (AML) with their hematopoietic stem cell (HSC) therapies. Vor’s lead product is VOR33, an allogeneic CRISPR/Cas9 genome-edited HSC engineered to lack the CD33 protein to mitigate off-target effects of anti-CD33 therapies. 

VOR33 previously received fast track designation from the FDA earlier in September 2021.1 It is currently being investigated in a recruiting phase 1/2 trial (NCT04849910) with a target enrollment of 18 participants. Primary completion is expected in May 2023.

The company uses their Vor HSC platform to develop their therapies and has identified additional surface targets such as CD123 and CLL-1 for future research. Vor also recently partnered with Janssen to improve the tolerability of 1 of Janssen’s bispecific antibody treatments with the use of the Vor platform.2 

GeneTherapyLive spoke with Robert Ang, MBBS, MBA, chief executive officer, and Christopher Slapak, MD, chief medical officer, both of Vor Biopharma, to learn more about their focus on mitigating toxicities in cancer therapies by protecting HSCs. They also discussed the company’s progress with VOR33.

REFERENCES
1. PureTech founded entity Vor Biopharma announces VOR33 granted U.S. Fast Track designation for Acute Myeloid Leukemia. Business Wire. News release. September 10, 2021. https://www.businesswire.com/news/home/20210909006184/en
2. Vor Biopharma announces collaboration with Janssen to develop engineered hematopoietic stem cell transplants combined with a bi-specific antibody therapy for acute myeloid leukemia (AML). News release. Vor Biopharma. July 8, 2021. https://ir.vorbio.com/news-releases/news-release-details/vor-biopharma-announces-collaboration-janssen-develop-engineered

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.